KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Asset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryDepreciation & Amortization (CF)Exchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Novavax (NVAX) Gains from Investment Securities: 2010-2025

Historic Gains from Investment Securities for Novavax (NVAX) over the last 13 years, with Sep 2025 value amounting to $3.9 million.

  • Novavax's Gains from Investment Securities rose 252.87% to $3.9 million in Q3 2025 from the same period last year, while for Sep 2025 it was $26.8 million, marking a year-over-year increase of 339.36%. This contributed to the annual value of $21.8 million for FY2024, which is 20.25% down from last year.
  • Per Novavax's latest filing, its Gains from Investment Securities stood at $3.9 million for Q3 2025, which was down 81.94% from $21.5 million recorded in Q2 2025.
  • Novavax's 5-year Gains from Investment Securities high stood at $64.0 million for Q4 2021, and its period low was -$16.6 million during Q1 2025.
  • Its 3-year average for Gains from Investment Securities is $5.3 million, with a median of $2.3 million in 2023.
  • Per our database at Business Quant, Novavax's Gains from Investment Securities spiked by 3,462.64% in 2021 and then plummeted by 488.96% in 2024.
  • Novavax's Gains from Investment Securities (Quarterly) stood at $64.0 million in 2021, then decreased by 25.52% to $47.7 million in 2022, then slumped by 95.14% to $2.3 million in 2023, then soared by 677.19% to $18.0 million in 2024, then spiked by 252.87% to $3.9 million in 2025.
  • Its last three reported values are $3.9 million in Q3 2025, $21.5 million for Q2 2025, and -$16.6 million during Q1 2025.